A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
2SPD-029 Off-label drugs: use analysis and pharmacoepidemiology in a COVID centre in Rome
2021
Section 2: Selection, procurement and distribution
unpublished
Preserved Fulltext
Conclusion and relevance BM expenditure increased by more than 50% in the last five years, with MAb being mainly responsible. The biological active substances with the highest budgetary impact were medicines to treat immune mediated diseases. The incorporation of BS will lead to a reduction of 20% in BM costs.
doi:10.1136/ejhpharm-2021-eahpconf.12
fatcat:fuz3aw4bhjbinlntekgkkwvus4